WASHINGTON (Legal Newsline) – The Federal Trade Commission is suing several major pharmaceutical companies, saying they illegally blocked consumer access to lower-cost versions of the drug AndroGel.

Adult males who have conditions associated with a deficiency or absence of endogenous testosterone will soon have a new generic treatment, pending the Food and Drug Administration’s final approval.

AndroGel (testosterone gel) is prescribed to treat low testosterone levels. AndroGel’s cost may depend on your dosage and whether you have health insurance. It also may depend on the pharmacy you use ...

Androgel (testosterone) is a brand-name topical gel that’s prescribed for low testosterone due to certain medical conditions in adults. The cost of the drug with and without insurance can depend on ...

(Reuters) - Any way you look at it, AbbVie ABBV.N predecessor Abbott Laboratories ABT.N made a bad decision when it sued generic drug maker Perrigo PRGO.N in 2011, as Perrigo geared up to bring a ...

Testim, which delivered sales of $211.2 million last year, is under significant pressure with the product expected to post revenues of less than $85 million this year. Challenges being faced by Testim ...

SALEM, Ore. (KTVZ) -- In what he called a groundbreaking case, Oregon Attorney General Dan Rayfield said Friday he has reached a settlement involving a monopoly on testosterone replacement gels. The ...

The feds are not big fans of a drug company paying generics manufacturers to stave off competition. A reminder: The Federal Trade Commission has sued to block a deal that the antitrust watchdogs say ...

NEW YORK (Reuters) - The U.S. Food and Drug Administration said on Thursday it will require strong warnings to be added to two testosterone replacement gel products after numerous reports of troubling ...

DEAR DR. ROACH: I am an 84-year-old male. I recently switched from testosterone patches to AndroGel. My testosterone levels have gone up considerably, and I have seen some improvement in my erectile ...

San Francisco, Calif. and Torrance, Calif. (June 20, 2002) – A Phase 3 study conducted at multiple research centers in the U.S. under the direction of Ronald Swerdloff, MD, Principal Investigator at ...